One canonical Retatrutide page for MedCore 10 mg and 20 mg presentations, with current Phase 3 research status and FDA unapproved-drug context clearly separated from product information.
PubChem identifies Retatrutide, also known as LY-3437943, as an investigational peptide and links it to ongoing clinical development. Curated pharmacology records describe activity at glucagon, GIP and GLP-1 receptors.1
ClinicalTrials.gov lists Phase 3 studies of Retatrutide, including TRANSCEND-T2D-1 (NCT06354660), which is marked completed with no results posted in the public record at the time of this review.2
Because the compound remains investigational, current clinical-trial and FDA status is more important than generic promotional language.
ClinicalTrials.gov lists NCT06354660, a Phase 3 randomized study comparing Retatrutide with placebo in adults with type 2 diabetes and inadequate glycemic control. The record shows the study as completed, with actual enrollment of 537 and no results posted at the time of review.2
FDA states that Retatrutide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law.3
PubChem identifies Retatrutide/LY-3437943 and links the compound to its clinical research program.1
Both strengths remain on one canonical investigational-compound page to avoid duplicating the same clinical-status and regulatory evidence.
A MedCore 10 mg Retatrutide research presentation within one canonical investigational-compound profile.
A separate MedCore 20 mg Retatrutide presentation represented on the same canonical entity page.
MedCore documentation can describe each presentation without implying approval, clinical-trial participation or equivalence to sponsor investigational material.
Strength-specific documentation preview for the MedCore Retatrutide research presentation.
These images are presented as sample product documentation and should not be interpreted as independently verified analytical certification. Product identity, batch data and analytical claims should be checked against original laboratory records.
Related metabolic-research entities form a topical cluster while preserving separate regulatory status.
Answer-first content keeps Phase 3 development, FDA status and MedCore product information distinct.
The page prioritizes current clinical-trial status and FDA regulatory statements because Retatrutide remains investigational. Last reviewed 2 September 2026.
Curated investigational-compound identity and clinical-research links.
Open PubChem source ↗Phase 3 Retatrutide study record, study status and enrollment information.
Open ClinicalTrials.gov ↗FDA statement that Retatrutide is not a component of an FDA-approved drug, has not been found safe and effective, and cannot be used in compounding under federal law.
Open FDA source ↗Review the quality framework or contact MedCore for product-specific documentation.
